Abstract 21P
Onxeo has pioneered a radically new approach of anti-cancer treatment to tackle emergence of resistance: the decoy agonist mechanism of action (MoA). Drugs based on this unprecedented MoA hijack and hyper activate therapeutic targets (decoy effect) leading to exhaustion (agonist effect). This breakthrough MoA has already shown, using our lead compound AsiDNA, target engagement and excellent safety profile in humans and importantly lack of resistance in multiple preclinical studies. These exciting results led us to develop a proprietary platform of oligonucleotides (platON) with decoy agonist properties: the new generation product OX401 targeting PARP, a target already validated in oncology.